May & Baker Nigeria plc (NGX:MAYBAKER)

Nigeria flag Nigeria · Delayed Price · Currency is NGN
16.25
0.00 (0.00%)
At close: Sep 12, 2025
Market Cap28.04B
Revenue (ttm)34.22B
Net Income (ttm)2.34B
Shares Out1.73B
EPS (ttm)1.36
PE Ratio11.96
Forward PEn/a
Dividend0.40 (2.46%)
Ex-Dividend DateMay 21, 2025
Volume206,772
Average Volume601,517
Openn/a
Previous Close16.25
Day's Rangen/a
52-Week Range6.60 - 19.50
Beta0.17
RSI33.36
Earnings DateOct 27, 2025

About May & Baker Nigeria

May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic, anti-hypersensitive, anti-infective, anti-malaria, analgesic, cough and cold, and anxiolytics; and nature care products. It also provides beverage drinks, including bottled water under the Lily Water name; and hand and surface sanitizers under the Smartans name. ... [Read more]

Industry Pharmaceutical Preparations
Founded 1944
Employees 396
Stock Exchange Nigerian Stock Exchange
Ticker Symbol MAYBAKER
Full Company Profile

Financial Performance

In 2024, May & Baker Nigeria's revenue was 28.91 billion, an increase of 46.76% compared to the previous year's 19.70 billion. Earnings were 1.62 billion, an increase of 49.67%.

Financial Statements

News

May & Baker to commercialise bitterleaf capsule, unveil bio-vaccine factory

“May & Baker has gone through stages since its inception on September 4, 1944, as Nigeria’s first pharmaceutical company." The post May & Baker to commercialise bitterleaf capsule, unveil bio-vaccine ...

1 year ago - Premium Times Nigeria